

Exhibit A

- 88. (Amend) The composition of claim 78, wherein the amount of the saponin is an amount between about [1] 10 ug and about [100] 200 ug.--
- 94. (Amended) A method of [preventing or] treating a cancer in a subject which comprises administering to the subject an effective cancer [preventing or] treating amount of a composition which comprises:
- b) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion, to ii) Keyhole Limpet Hemocyanin;
 - b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
 - c) a pharmaceutically acceptable carrier;
- the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject,
- wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a ceramide-derived carbon of the ganglioside derivative to Keyhole Limpet Hemocyanin, so as to thereby [prevent or] treat [a] the cancer in the subject.--
- 95. (Amended) The method of claim [93 or] 94, wherein the cancer is of epithelial origin.--
- 96. (Amended) The method of claim [93 or] 94, wherein the

Applicants: Philip Livingston and Friedhelm Helling

Serial No.: 08/477,097

Filed: June 7, 1995

Page 25

cancer is of neuroectodermal origin.--

--98. (Amended) The method of [any one of claims 92-] claim 92
or 94, wherein the administering is effected at two or
more sites.--

--99. (Amended) The method of claim [95] 98, wherein the
administering is effected at three sites.--